BCMA Targeted Therapies Market Research is Expecting to Accrue Strong Growth in Forecast to 2035
The global BCMA targeted therapies market, valued at USD 9.2 billion in 2024, is projected to reach USD 11.8 billion in 2025 and USD 85.9 billion by 2035, representing a CAGR of 21.9% during the forecast period. B-cell maturation antigen (BCMA), an important biomarker of the B-cells, has emerged as a promising therapeutic target for the treatment of multiple myeloma and other hematological malignancies. The antigen is universally expressed on the surface of multiple myeloma cells.
source of information: https://www.rootsanalysis.com/....reports/bcma-targete
Like
Comment
Share
1 (877) 773-1002